Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab + golimumab versus guselkumab in active psoriatic arthritis after prior anti-TNF inadequate response
2021-002012-31Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab + golimumab combination therapy with Guselkumab monotherapy (2 arms). Primary endpoint: Proportion of participants who achieve minimal disease activity at Week 24. Started Aug 2021; status: active.
02
Drugs
guselkumabgolimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2021-002012-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002012-31.